Venn Life Sciences Holdings PLC Board Appointment (9595Z)

TIDMVENN

RNS Number : 9595Z

Venn Life Sciences Holdings PLC

14 March 2013

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Board Appointment

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the appointment of Paul Kennedy as Non-Executive Director with immediate effect.

Paul has an extensive career in the pharmaceutical industry having been President of Novo Nordisk France for 15 years and before that working as a Marketing Director for seven years at Abbot France and Boots, both in the UK and France. Having left Novo Nordisk in 1994, Paul set up his own pharmaceutical company, Laboratoires Murat, which was purchased by Fuisz Technologies Ltd, a Nasdaq listed drug delivery company three years later. Paul then worked as Executive Vice President, Operations for Fuisz Technologies in Paris before the business was sold to Shire plc in 1999 for a further premium.

From 1999 to 2004 Paul worked as an Independent Consultant in the pharmaceutical industry where he continued to build on his M&A experience by advising on a series of transactions, including the sale of Ethypharm for EUR235m and the sale of Laboratoires Dexo for EUR12.5m. In 2004 Paul became President of International Operations at AIM listed medical diagnostics company Cozart plc, establishing their international organisation from a standing start. Cozart was subsequently sold for GBP65m in 2007 to Concateno plc. In 2007 Paul became a controlling shareholder and Director of US listed IVAX Diagnostics, Inc, which was subsequently sold to Transasia Bio-Medicals Ltd, India's largest diagnostics company, in September 2010. Paul is also fluent in French and Spanish.

Commenting on the appointment, Venn CEO, Tony Richardson, said: "We are very pleased to welcome Paul to the Board as a Non-Executive Director. Paul's knowledge of the pharmaceutical and medical diagnostics industries, and particularly his experience in M&A transactions, will be a great benefit to Venn as we continue to execute our strategy of becoming a leading mid-sized CRO in Europe."

Enquiries:

 
 Venn Life Sciences Holdings Plc 
 Tony Richardson, Chief Executive Officer                        Tel: +353 154 99 341 
 Paul Foulger, Finance Director                                    Tel: 020 7245 1100 
 
 Zeus Capital (Nominated Adviser and 
  Broker) 
 Ross Andrews/Andrew Jones(Corporate                               Tel: 0161 831 1512 
  Finance) 
 John Goold (Institutional Sales)                                  Tel: 020 7016 8925 
 
 Walbrook PR Ltd                            Tel: 020 7933 8787 or venn@walbrookpr.com 
 Paul McManus                                                      Mob: 07980 541 893 
 Lianne Cawthorne                                                  Mob: 07584 391 303

Additional Information:

Paul Francis Kennedy, aged 68, holds 480,035 shares in the Company and other than as set out below there is no further information to be disclosed under schedule 2(g) and Rule 17 of the AIM Rules in respect of Mr Kennedy's appointment today as a Director of the Company.

Paul is a director / partner or has been a director / partner of the following companies / partnerships during the previous five years:

 
 Current directorships/partnerships   Director/Partner in the last 5 years 
-----------------------------------  ------------------------------------- 
 None                                 IVAX Diagnostics, Inc 
-----------------------------------  -------------------------------------

About Venn Life Sciences Limited: www.vennlifesciences.com

Venn Life Sciences is a Clinical Research Organisation ("CRO") providing a suite of consulting and clinical trial services to pharmaceutical, biotechnology and medical device organisations and having operations in France, the Netherlands, Russia and Ireland, with a branch office in Switzerland. The Venn Group also includes a Clinical Resourcing business based in France. The Company's near term objective is the expansion of its coverage to other European countries through strategic acquisitions thus combining a number of small European CROs to build a mid-sized CRO focused on the European market, offering clients a full service, multi-centred capability in Phase II-IV trials and across a range of principal disease areas.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOADXLFFXXFXBBD

Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024